ACTRN12612000137897
Not yet recruiting
Phase 2
A Phase II Single Arm Study Assessing The Feasibility And Toxicity Of Dose-Dense ABVD In Patients With Early Stage Unfavourable And Advanced Stage Hodgkin Lymphoma.
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Early Stage Unfavourable Hodgkin Lymphoma
- Sponsor
- Queensland Health
- Enrollment
- 31
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Confirmed histological diagnosis of Hodgkin Lymphoma
- •Staging consistent with either early stage unfavourable or advanced stage disease according to the GHSG staging system
- •ECOG performance status 0 to 2 inclusive
- •No prior therapy for Hodgkin Lymphoma except for a short course of steroids for initial symptom control
- •Written informed consent prior to study registration
- •Patients of child bearing potential must use adequate contraception
Exclusion Criteria
- •Prior or current disease which prevents treatment with protocol chemotherapy
- •Abnormal laboratory parameters (unless due to disease)
- •Concurrent or previous malignancy except adequately treated non\-melanoma skin cancer, curatively treated in\-situ cancer of the cervix or other solid tumours treated for cure with no evidence of disease for more than or equal to 2 years
- •Presence of positive test results in human immunodeficiency virus (HIV), Hepatitis B (HB surface antigen \[HBsAg], total HB core antibody \[anti\-HB\-c]) and Hepatitis C (Hepatitis C virus \[HCV] antibody) serology testing.
- •Likely inability of the patient to comply with treatment assessments
- •Pregnancy and lactation. Adults of reproductive potential must agree to use an effective method of birth control during treatment and for at least 3 months thereafter
- •Prior solid organ transplantation
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Addition of resveratrol copper with chemotherapy in gastric cancer patientsHealth Condition 1: C169- Malignant neoplasm of stomach, unspecifiedCTRI/2019/07/020289Tata Memorial Hospital
Terminated
Phase 2
A single arm, prospective Phase II study of Split-Course PelvicRadiotherapy for Locally Progressive, Castrate Resistant Prostate CancerCastrate Resistant Prostate CancerCancer - ProstateACTRN12614000858695Radiation Oncology Services - Mater Centre18
Active, not recruiting
Phase 1
A clinical study to assess the cobination of two drugs (177Lu-DOTATATE and nivolumab) in neuroendocrine tumourseuroendocrine neoplasms (Grade 3 well-differentiated neuroendocrine tumours (NET) or poorly differentiated neuroendocrine carcinomas (NEC))MedDRA version: 20.0 Level: PT Classification code 10057270 Term: Neuroendocrine carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0 Level: PT Classification code 10052399 Term: Neuroendocrine tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0 Level: LLT Classification code 10062476 Term: Neuroendocrine tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-002974-29-ESFundación de investigación de HM Hospitales30
Not yet recruiting
Not Applicable
A Phase II Single-Arm Study to Evaluate the Feasibility of Preoperative Rehabilitation and Nutrition Intervention in Patients Undergoing Resection for Hepato-Pancreato-Biliary Surgeries.HBP malignancies (major hepatectomy, pancreatoduodenectomy)JPRN-UMIN000048073Keio University60
Recruiting
Not Applicable
A Phase II Single-Arm Study to Evaluate the Feasibility of Preoperative Rehabilitation and Nutrition Intervention in Patients Undergoing Neoadjuvant Chemotherapy for Esophageal Canceresophageal cancerJPRN-UMIN000045479Keio University33